Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4741886 | 0.81 | PDGFRB (0.60) | GPBAR1PDGFRBPDGFRANPC1MAOB | |
| SCHEMBL4742392 | 0.81 | BACE1 (0.46) | GPBAR1PDGFRBPDGFRAMAOAERN1 | |
| SCHEMBL4739252 | 0.80 | GPBAR1 (0.55) | GPBAR1PDGFRBPDGFRAERN1TRIM24 | |
| SCHEMBL4740452 | 0.79 | GPBAR1 (0.56) | GPBAR1PDGFRBPDGFRANPC1MAOB | |
| SCHEMBL4741387 | 0.78 | GPBAR1 (0.57) | GPBAR1PDGFRBPDGFRANPC1MAOB | |
| SCHEMBL4741474 | 0.78 | GPBAR1 (0.69) | GPBAR1PDGFRBPDGFRANPC1MAOB | |
| SCHEMBL7998293 | 0.77 | ERN1 (0.51) | GPBAR1PDGFRBPDGFRANPC1MAOB | |
| SCHEMBL4741461 | 0.77 | ERN1 (0.48) | GPBAR1ERN1ALDH1A1 | |
| SCHEMBL4740519 | 0.77 | GPBAR1 (0.53) | GPBAR1PDGFRBPDGFRAERN1ALDH1A1 | |
| SCHEMBL4871895 | 0.76 | KDM4E (0.52) | GPBAR1NPC1ERN1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221161-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221161-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221161-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| WO-2008097976-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008097976-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221161-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | GPR119, GPBAR1, LDLR | GPBAR1 2/4885PDGFRB 1505/4885PDGFRA 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.